Related Experiment Video

Updated: Mar 1, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.4K

Insulin glulisine for continuous subcutaneous insulin infusion in pediatric type 1 diabetes

Tatsuhiko Urakami1, Yusuke Mine1, Masako Aoki1

  • 1Department of Pediatrics, Nihon University School of Medicine, Tokyo, Japan.

Pediatrics International : Official Journal of the Japan Pediatric Society
|May 26, 2017
PubMed

Insights

Insulin glulisine (GLU) improved post-meal glucose levels and reduced hemoglobin A1c and hypoglycemia frequency in children with type 1 diabetes using continuous subcutaneous insulin infusion (CSII). GLU is an effective treatment option for pediatric type 1 diabetes management.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Background:

  • Type 1 diabetes (T1D) requires intensive management, often involving continuous subcutaneous insulin infusion (CSII).
  • Rapid-acting insulin analogues are crucial for mealtime glucose control in T1D.
  • Evaluating the long-term efficacy and safety of specific insulin analogues in pediatric CSII is essential.

Purpose of the Study:

  • To assess the efficacy and safety of insulin glulisine (GLU) for CSII in children with T1D over one year.
  • To determine the impact of GLU on glycemic control, including postprandial glucose levels and HbA1c.
  • To evaluate changes in the frequency of hypoglycemia during GLU treatment.

Main Methods:

  • A cohort of 20 children with T1D was studied over one year of GLU treatment via CSII.
  • Plasma glucose levels were measured before and after meals (breakfast, dinner).
  • Hemoglobin A1c (HbA1c) levels and the frequency of hypoglycemic events were recorded.

Main Results:

  • Significant improvements were observed in post-breakfast (192.5 to 162.0 mg/dL) and post-dinner (191.1 to 161.1 mg/dL) glucose levels (P < 0.01).
  • Mean HbA1c significantly decreased from 8.0% to 7.7% (P < 0.05).
  • The mean monthly frequency of hypoglycemia significantly reduced from 8.3 to 6.0 events (P < 0.05).

Conclusions:

  • Insulin glulisine (GLU) demonstrates efficacy in improving postprandial glycemic control in pediatric T1D patients using CSII.
  • GLU treatment led to a significant reduction in HbA1c and hypoglycemia frequency.
  • Insulin glulisine is a viable and effective treatment option for children with type 1 diabetes managed with CSII.

Keywords:
childrencontinuous s.c. insulin infusionglycemic controlhypoglycemiainsulin glulisine

More Related Videos

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

10.9K
Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas04:41

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Published on: July 25, 2025

1.0K

Related Concept Videos

Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
875
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
957
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
760
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.7K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
2.8K